Novartis gets FDA nod for breast cancer drug combo Piqray plus fulvestrant

This article was originally published here

The FDA has approved Piqray kinase inhibitor in combination with fulvestrant to treat postmenopausal women, and men with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-),

The post Novartis gets FDA nod for breast cancer drug combo Piqray plus fulvestrant appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply